Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02133183 : Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
PhaseN/A
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

- Patients must have histologically proven glioblastoma or gliosarcoma which is
progressive or recurrent following radiation therapy +/- chemotherapy

- Patients must have measurable, supratentorial contrast-enhancing progressive or
recurrent glioblastoma or gliosarcoma by magnetic resonance imaging (MRI) imaging
within 21 days of starting treatment; patient must be able to tolerate MRIs

- Patients may have had treatment for no more than 2 prior relapses

- Patients must have recovered from severe toxicity of prior therapy; the following
intervals from previous treatments are required to be eligible:

- 12 weeks from the completion of radiation

- 6 weeks from a nitrosourea chemotherapy or mitomycin C

- 3 weeks from a non-nitrosourea chemotherapy

- 4 weeks from any investigational (not Food and Drug Administration
[FDA]-approved) agents

- 2 weeks from administration of a non-cytotoxic, FDA-approved agent except
bevacizumab/vascular endothelial growth factor receptor (VEGFR) inhibitors (e.g.,
erlotinib, hydroxychloroquine, etc.)

- 6 weeks from bevacizumab/VEGFR inhibitors

- Patients must be undergoing surgery that is clinically indicated as determined by
their care providers

- Patients must be eligible for surgical resection according to the following criteria:

- Part 1 Patients: Expectation that the surgeon is able to resect at least 350 mg
of tumor from enhancing tumor and at least 350 mg from non-enhancing tumor with
low risk of inducing neurological injury

- Part 2 Patients: Expectation that the surgeon is able to resect at least 1000 mg
from enhancing tumor and at least 350 mg from non-enhancing tumor with low risk
of inducing neurological injury

- Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be
able to care for himself/herself with occasional help from others)

- Absolute neutrophil count >= 1,500/mcL

- Platelets >= 100,000/mcL

- Hemoglobin >= 9 g/dL

- Total bilirubin =< 1.5 x upper limit of normal (ULN)

- Fasting serum glucose =< 130 MG/DL

- HbA1c < 7.0%

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
=< 2.5 × institutional upper limit of normal

- Creatinine =< institutional upper limit of normal OR

- Creatinine clearance >= 50 ml/min/1.73 m^2 for patients with creatinine levels above
institutional normal

- Activated partial thromboplastin time (APTT)/partial thromboplastin time (PTT) =< 1.5
x institutional upper limit of normal

- Patients must be able to provide written informed consent

- Women of childbearing potential must have a negative serum pregnancy test prior to
study entry; women of childbearing potential and men must agree to practice 1 highly
effective method of contraception and 1 additional effective (barrier) method, at the
same time, prior to study entry, for the duration of study participation, and through
90 days (or longer, as mandated by local labeling [e.g. USPI, SmPC, etc.]) after the
last dose of study drug; should a woman become pregnant or suspect she is pregnant
while participating in this study, she should inform her treating physician
immediately; men treated or enrolled on this protocol must also agree to use highly
effective barrier contraception prior to the study, for the duration of study
participation, and through 120 days after the last dose of study drug

- Patients must have no concurrent malignancy except curatively treated basal or
squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or
bladder; patients with prior malignancies must be disease-free for >= five years

- Patients must be able to swallow whole capsules

- Patients enrolled in Part 2 must have at least 20 (preferably 40) slides of archival
tumor tissue from a prior surgery demonstrating GBM; patients enrolled in Part 1 will
not be required to have archival tissue

- Patients with controlled diabetes are allowed on study; controlled diabetes is defined
as < 130 ml/dL for the sake of this study

Exclusion Criteria:

- Patients receiving any other investigational agents are ineligible

- Patients with a history of allergic reactions attributed to compounds of similar
chemical or biologic composition to MLN0128 (TAK-228) are ineligible

- Patients may not have had prior treatment with mTOR, peptidase inhibitor 3,
skin-derived (PI3) kinase or Akt inhibitors

- Patients on enzyme-inducing anti-epileptic drugs (EIAED) are not eligible for
treatment on this protocol; patients may be on non-enzyme inducing anti-epileptic
drugs or not be taking any anti-epileptic drugs; patients previously treated with
EIAED may be enrolled if they have been off the EIAED for 10 days or more prior to the
first dose of MLN0128 (TAK-228)

- Patients must not have evidence of significant hematologic, renal, or hepatic
dysfunction

- Patients must not have evidence of significant intracranial hemorrhage

- Patients with a history of any of the following within the last 6 months prior to
study entry are ineligible:

- Ischemic myocardial event, including angina requiring therapy and artery
revascularization procedures

- Ischemic cerebrovascular event, including transient ischemic attack (TIA) and
artery revascularization procedures

- Requirement for inotropic support (excluding digoxin) or serious (uncontrolled)
cardiac arrhythmia (including atrial flutter/fibrillation, ventricular
fibrillation or ventricular tachycardia)

- Placement of a pacemaker for control of rhythm

- New York Heart Association (NYHA) class III or IV heart failure

- Pulmonary embolism

- Patients with known significant active cardiovascular or pulmonary disease at the time
of study entry are ineligible

- Patients with baseline prolongation of the rate-corrected QT interval (QTc) (e.g.,
repeated demonstration of QTc interval > 480 milliseconds, or history of congenital
long QT syndrome, or torsades de pointes) are ineligible

- Patients with known diabetes mellitus which is poorly controlled (defined as
hemoglobin A1c [HbA1c] > 7%) are ineligible; subjects with a history of transient
glucose intolerance due to corticosteroid administration are allowed in this study if
all other inclusion/exclusion have been met

- Patients who have initiated treatment with bisphosphonates less than 30 days prior to
the first administration of MLN0128 (TAK-228) are ineligible; concurrent
bisphosphonate use is only allowed if the bisphosphonate was initiated at least 30
days prior to the first administration of MLN0128 (TAK-228)

- For weekly MLN0128 (TAK-228) dose cohorts, patients taking proton pump inhibitors
(PPIs) are ineligible unless these patients are able to switch to a histamine (H2)
blocker and/or antacid

- Patients with known manifestations of malabsorption due to prior gastrointestinal (GI)
surgery, GI disease, or for an unknown reason that may alter the absorption of MLN0128
(TAK-228) are ineligible

- Patients with uncontrolled intercurrent illness including, but not limited to, ongoing
or active infection, symptomatic congestive heart failure, unstable angina pectoris,
cardiac arrhythmia, or psychiatric illness/social situations that would limit
compliance with study requirements, are ineligible

- Pregnant women are excluded from this study; breastfeeding should be discontinued if
the mother is treated with this agent

- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
therapy are ineligible

- Subjects taking strong CYP3A4 and CYP2C19 inhibitors and/or inducers should be
considered with caution; alternative treatments that are less likely to affect MLN0128
(TAK-228) metabolism, if available, should be considered; if a subject requires
treatment with 1 or more of the strong CYP3A4 and CYP2C19 inhibitors and/or inducers,
the study doctor should be consulted
LinksPermanent Link to THIS page: http://virtualtrials.com/nct/display1trial.cfm?nct=NCT02133183      |      Link to official Clinicaltrials.gov listing
Locations
Baltimore, Maryland
Facility: Johns Hopkins University/Sidney Kimmel Cancer Center
Investigator: Stuart A. Grossman
Contact: Stuart A. Grossman Phone: 410-955-8804
Click HERE to send email to this center

Boston, Massachusetts
Facility: Dana-Farber Cancer Institute
Investigator: Eudocia Q. Lee
Contact: Eudocia Q. Lee Phone: 877-726-5130
Email not avaialable

Detroit, Michigan
Facility: Henry Ford Hospital
Investigator: Tobias Walbert
Contact: Tobias Walbert Phone: 313-916-1784
Email not avaialable

Winston-Salem, North Carolina
Facility: Wake Forest University Health Sciences
Investigator: Glenn J. Lesser
Contact: Glenn J. Lesser Phone: 336-713-6771
Email not avaialable

Cleveland, Ohio
Facility: Case Western Reserve University
Investigator: David M. Peereboom
Contact: David M. Peereboom Phone: 866-223-8100
Email not avaialable

Cleveland, Ohio
Facility: Cleveland Clinic Foundation
Investigator: David M. Peereboom
Contact: David M. Peereboom Phone: 866-223-8100
Email not avaialable

Pittsburgh, Pennsylvania
Facility: University of Pittsburgh Cancer Institute (UPCI)
Investigator: Frank S. Lieberman
Contact: Frank S. Lieberman Phone: 724-773-7616
Email not avaialable




Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites